Singapore markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.2100-0.1700 (-3.88%)
At close: 04:00PM EDT
4.1900 -0.02 (-0.48%)
After hours: 07:31PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.3800
Open4.3700
Bid4.1800 x 300
Ask4.2600 x 800
Day's range4.1800 - 4.4200
52-week range4.1800 - 9.0700
Volume3,808,518
Avg. volume3,175,591
Market cap867.892M
Beta (5Y monthly)1.93
PE ratio (TTM)N/A
EPS (TTM)-1.1800
Earnings date06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.82
  • Simply Wall St.

    With 80% ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) boasts of strong institutional backing

    Key Insights Significantly high institutional ownership implies BioCryst Pharmaceuticals' stock price is sensitive to...

  • GlobeNewswire

    BioCryst to Report First Quarter 2024 Financial Results on May 6

    RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live

  • GlobeNewswire

    BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

    RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. “We are excited to announce that ORLADEYO is now approved in the region’s largest market, following the positive regulatory decisions w